Velpanat (Sofosbuvir/Velpatasvir) 400 mg / 100 mg

Velpanat is formulated as film-coated, capsule-shaped blue tablets with debossing on one side:

• Presentation and Packaging: Supplied in an original white High-Density Polyethylene (HDPE) bottle equipped with a child-resistant cap. Each bottle contains 28 film-coated tablets (a precise 4-week / 28-day supply). The bottle is packaged in a factory-sealed printed cardboard box with patient information leaflet.
• Active Ingredients (per tablet):
  • Sofosbuvir I.P. — 400 mg.
  • Velpatasvir I.P. — 100 мг.
• Inactive Excipients: Copovidone, microcrystalline cellulose (E460), croscarmellose sodium (E468), magnesium stearate (E470b), colloidal silicon dioxide.
• Film Coating: Opadry II Blue (hypromellose, titanium dioxide (E171), polyethylene glycol, indigo carmine, Brilliant Blue FCF aluminum lake (E133)).

Pharmacodynamics: Velpanat combines two synergistic direct-acting antiviral agents targeting separate non-structural proteins essential for HCV replication:

• Sofosbuvir: A nucleotide analog prodrug that is intracellularly metabolized in hepatocytes to form the pharmacologically active nucleoside triphosphate (GS-461203). This active triphosphate acts as a chain terminator by incorporating into viral RNA via the NS5B RNA-dependent RNA polymerase, stopping viral replication. Sofosbuvir possesses a high genetic barrier to resistance.
• Velpatasvir: A potent pangenotypic inhibitor of the HCV NS5A non-structural protein. The NS5A protein is indispensable for both viral RNA replication and the assembly/secretion of new HCV virions. Inhibiting NS5A blocks viral propagation to uninfected hepatocytes.

Pharmacokinetics:

• Absorption: Following oral administration, sofosbuvir and velpatasvir are rapidly absorbed. Peak plasma concentration (Cmax) of sofosbuvir is reached within 0.5–2 hours, while its major active metabolite GS-331007 reaches peak levels at 2–4 hours. Velpatasvir median Cmax is reached at 3 hours. High-fat meals do not significantly alter sofosbuvir exposure but slightly increase velpatasvir AUC.
• Distribution: Sofosbuvir protein binding is approximately 61–65%, whereas velpatasvir is extensively bound to human plasma proteins (>99.5%).
• Metabolism & Elimination: Sofosbuvir is extensively metabolized in the liver to form GS-331007, which is primarily excreted by the kidneys (~80%). Velpatasvir undergoes minimal CYP2B6, CYP2C8, and CYP3A4 metabolism and is eliminated mostly unchanged in feces (~94%). Terminal elimination half-life (T1/2) is ~15 hours for GS-331007 and ~15–17 hours for velpatasvir.

Velpanat is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adult and pediatric patients aged 12 years and older (weighing at least 30 kg):

• 🔹 Chronic HCV Genotypes 1–6: Treatment of patients infected with HCV genotypes 1a, 1b, 2, 3, 4, 5, or 6.
• 🔹 Patients Without Cirrhosis or With Compensated Cirrhosis: Individuals with METAVIR stages F0–F4 (Child-Pugh Class A) — recommended 12-week Velpanat monotherapy.
• 🔹 Patients With Decompensated Cirrhosis: Individuals with Child-Pugh Class B or C disease — recommended 12-week course of Velpanat combined with Ribavirin.
• 🔹 HCV/HIV-1 Co-infected Patients: Safety and efficacy profiles match those of HCV mono-infected individuals (subject to antiretroviral regimen selection).
• 🔹 Treatment-Experienced Patients: Indicated for patients who failed prior therapies with pegylated interferon plus ribavirin or sofosbuvir monotherapy.

Adherence to dosage guidelines is vital for preventing viral breakthrough and therapeutic failure:

• 💊 Recommended Dosage: Take one tablet (400 mg sofosbuvir / 100 mg velpatasvir) orally once daily.
• 🥤 Administration Method: Swallow the tablet whole with a glass of water (100–200 mL). Do not crush, chew, break, or dissolve the tablet due to its bitter taste and potential disruption of controlled release parameters.
• ⏰ Timing: Take the tablet at a consistent time every day (e.g., every morning at 9:00 AM). May be taken with or without food; taking it during a light meal can minimize mild stomach distress.
• ⏱️ Treatment Duration:
  • Non-cirrhotic & Compensated Cirrhosis (Child-Pugh A): 12 consecutive weeks (3 bottles / 84 tablets total).
  • Decompensated Cirrhosis (Child-Pugh B or C): 12 consecutive weeks combined with weight-based Ribavirin (1000 mg/day for <75 kg; 1200 mg/day for ≥75 kg). If ribavirin is contraindicated, treatment may be extended to 24 weeks.
• ⚠️ Missed Dose Protocol: If missed by less than 18 hours, take the missed dose immediately and resume regular schedule. If over 18 hours have passed, skip the missed tablet and resume normal dosing. Never take a double dose.
• 🤢 Vomiting Management: If vomiting occurs within 3 hours of administration, take an additional tablet. If vomiting occurs after 3 hours, no additional dose is required.

Velpanat administration is strictly contraindicated under the following conditions:

• ❌ Known hypersensitivity or severe allergic reaction to Sofosbuvir, Velpatasvir, or any formulation excipients.
• ❌ Co-administration with potent P-glycoprotein (P-gp) inducers or CYP2B6, CYP2C8, CYP3A4 inducers (e.g., rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. John’s Wort Hypericum perforatum), as these drastically reduce plasma drug levels causing treatment failure.
• ❌ Co-administration with the antiarrhythmic agent Amiodarone — risks life-threatening symptomatic bradycardia and cardiac arrest.
• ❌ Children under 12 years of age or weighing under 30 kg (safety and efficacy remain unestablished).
• ❌ Pregnancy and breastfeeding (when combined with Ribavirin, contraindications extend to both male and female partners).

Velpanat exhibits important drug-drug interactions requiring clinical evaluation before therapy initiation:

• ⚠️ Gastric Acid-Reducing Agents (Antacids, H2-Blockers, Proton Pump Inhibitors / PPIs): Velpatasvir solubility decreases as gastric pH increases.
  • Antacids (aluminum/magnesium hydroxide): Separate administration by at least 4 hours before or after Velpanat.
  • H2-receptor antagonists (famotidine): Administer simultaneously or 12 hours apart at doses not exceeding famotidine 40 mg twice daily.
  • Proton Pump Inhibitors (omeprazole): Doses up to omeprazole 20 mg daily can be taken simultaneously with Velpanat with food 30 minutes prior to PPI.
• ⛔ Cardiac Medications: Co-administration with Amiodarone is strictly contraindicated. Digoxin levels require close monitoring due to increased plasma concentrations.
• ⚠️ HMG-CoA Reductase Inhibitors (Statins): Co-administration increases concentrations of rosuvastatin, atorvastatin, and simvastatin, elevating myopathy/rhabdomyolysis risks. Rosuvastatin dose should not exceed 10 mg daily.
• ⚠️ Anticoagulants: Patients taking warfarin or direct oral anticoagulants require frequent INR/coagulation monitoring due to hepatic function changes during viral clearance.
• ⚠️ HIV Antiretrovirals: Velpatasvir may increase tenofovir disoproxil fumarate (TDF) exposure, especially when combined with ritonavir or cobicistat. Monitor renal function closely.

Guidelines regarding Velpanat use during pregnancy and nursing:

• 🤰 Pregnancy: Adequate data on sofosbuvir/velpatasvir in pregnant women are lacking. As a precautionary measure, Velpanat use is not recommended during pregnancy. When prescribed with Ribavirin, the regimen is strictly contraindicated in pregnant women and male partners of pregnant women due to severe ribavirin-induced embryocidal and teratogenic risks. Effective contraception is required during treatment and for 6 months post-treatment.
• 🤱 Lactation: It is unknown whether sofosbuvir, its metabolites, or velpatasvir pass into human breast milk. Breastfeeding must be discontinued during Velpanat therapy.

In pivotal clinical trials (ASTRAL-1, ASTRAL-2, ASTRAL-3), the safety profile of sofosbuvir/velpatasvir matched placebo. Most reported adverse events were mild to moderate (Grade 1–2):

• 🔴 Very Common (≥1/10): Fatigue, headache, asthenia.
• 🟡 Common (≥1/100 to <1/10): Nausea, diarrhea, insomnia, decreased appetite, rash, arthralgia, myalgia.
• 🟠 Uncommon (≥1/1000 to <1/100): Allergic dermatitis, severe rash, angioedema (rare).
• 🟢 With Ribavirin Co-administration: Increased incidence of anemia (decreased hemoglobin), dyspnea, pruritus, hyperbilirubinemia.

Clinical experience with acute Velpanat overdose remains limited:

• Symptoms: No specific overdose toxidrome identified. Exaggerated adverse events (severe headache, dizziness, nausea) are expected.
• Management: No specific antidote exists. Treatment consists of gastric lavage, activated charcoal administration, and standard supportive care monitoring vital signs and ECG.
• Hemodialysis: Sofosbuvir’s primary metabolite GS-331007 is efficiently removed via hemodialysis (extraction ratio ~53%). Velpatasvir is highly protein-bound (>99.5%), making hemodialysis ineffective for its clearance.

Proper storage is essential to maintain full drug stability over its shelf life:

• 🌡️ Temperature: Store in original container below 30 °C. Avoid extreme heat fluctuations and freezing.
• ☀️ Moisture & Light Protection: Store exclusively inside the original factory HDPE bottle. Do not transfer tablets to pill organizers. Keep the silica gel desiccant canister inside the bottle.
• 👶 Safety: Keep out of reach of children and domestic pets. Keep bottle tightly closed.
• ⌛ Shelf Life: 24 months (2 years) from manufacturing date. Do not use past the expiration date printed on carton and label.

Velpanat by Natco Pharma Ltd. incorporates a state-of-the-art multi-tiered anti-counterfeiting verification system combining digital authentication and physical tamper-evident barriers:

• 📱 Digital Verification (QR Code & Hidden Secret Code): The carton features a specialized two-layer peel-off security label on the front. The top layer displays the manufacturer's web portal URL (www.natcopharma.co.in) and a scannable QR code. To verify authenticity, gently peel open the label starting from the bottom-right corner marked "To verify this product peel open the label here". Revealing the bottom layer uncovers a unique security code. Entering this code on Natco's authentication site or scanning via QR code provides immediate confirmation of product genuineness.
• 🛡️ Holographic Security Seal: The box opening flap is sealed with an authentic 3D rainbow holographic tape featuring the NATCO corporate logo. The seal incorporates a tamper-evident frangible layer that disintegrates upon unauthorized opening attempts.
• 🔍 Tamper-Evident Bottle Seals: The inner high-density HDPE plastic bottle features a safety break-ring cap. Underneath the cap, the bottle neck is hermetically sealed with a printed induction foil membrane to prevent product tampering.
• 📦 Factory Embossing & Packaging Quality: Key manufacturing details are deeply embossed on the side panel: Batch Number (Batch No.), Manufacturing Date (Mfg. Date), Expiry Date (Exp. Date), License Number (M.L.: 379/DR/Mfg./2014), and EAN barcode. Crisp, clear typography on heavy cardstock with compulsory "Schedule H Prescription Drug" box and "For India Only" label on the front.